Get the Stockscreener App
1.53
0.66%
0.01
After Hours:
1.49
-0.04
-2.61%
Inmune Bio Inc stock is traded at $1.53, with a volume of 187.53K.
It is up +0.66% in the last 24 hours and down -23.50% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.52
Open:
$1.5
24h Volume:
187.53K
Relative Volume:
0.81
Market Cap:
$42.46M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-0.9029
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
-4.97%
1M Performance:
-23.50%
6M Performance:
+9.29%
1Y Performance:
-15.93%
1-Day Range:
$1.46
$1.53
1-Week Range:
$1.40
$1.63
52-Week Range:
$1.09
$2.60
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.53 | 42.46M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Could Drug Research Partnership Just Shift Quantum Computing's (QUBT) Investment Narrative? - Simply Wall Street
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Form 4 Palisade Bio Inc: Julien E. Capers (Officer) For: 19 October - Investing.com UK
Form 8K INmune Bio Inc For: 21 October By Investing.com - Investing.com South Africa
UK approval could come about six weeks earlier, Inmune Bio (INMB) says of its revised Ebstrocel plan. - Stock Titan
A treatment for children with a skin disease could gain UK approval about six weeks sooner. - Stock Titan
Doctors may be able to request INmune Bio’s experimental cell therapy before local approval. - Stock Titan
Quantum Technology Meets Biotechnology: INmune Bio and Quantum Computing Inc. Team Up to Accelerate Drug Discovery - TheStreet
A quantum-computing company gets its first customer in pharma and biotech: INmune Bio - Stock Titan
Full Transcript: INmune Bio Q2 2026 Earnings Call - Benzinga
TRex Bio, Inc. Common stock (TRXB) company profile and facts - Yahoo Finance UK
TRex Bio, Inc. Common stock (TRXB) stock price, news, quote and history - Yahoo Finance UK
INmune Bio stock heads into Maxim summit before Q3 results - AD HOC NEWS
Quantum Computing Inc. Announces Dirac-3S, Scaling to Nearly 10,000 Variables - Stock Titan
Form 4 INmune Bio Inc For: 23 September - Investing.com India
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com UK
Inmune Bio (INMB) gives director 3-year option grant - Stock Titan
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan
A Sanofi rare-disease leader joins INmune Bio's board for a possible treatment launch. - Stock Titan
INmune Bio to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
Inmune Bio stock steadies as investors await next data catalyst - ad-hoc-news.de
INmune Bio undervalued as Ebstrocel for RDEB ne... - Pluang
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB) - Seeking Alpha
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - simplywall.st
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com Canada
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com India
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings - Yahoo Finance
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB - Investing.com
INmune (INMB) Financial Results: EPS Comes in Above Forecast on the Day; Post-Earnings: The Stock Gains 1.72% in the Latest ReadingEarnings Analysis - dars.gov.et
INmune Bio (INMB) Climbs 4.33% to $2.17 as Traders Test Key Resistance at $2.28Put Spread Alert - dars.gov.et
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com Nigeria
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - The Globe and Mail
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
7,211 |
10,095 |
1,518,017 |
| Moss David J | Chief Executive Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
9,014 |
12,620 |
1,294,883 |
44.16%
6.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):